Treatment of fungal and other opportunistic infections in immunocompromised patients

Leukemia

Volumn 11, Issue SUPPL. 4, 1997, Pages

  Wade, James C ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Fungal; Immunosuppression; Infection; Opportunistic

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; DOPAMINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TRIAZOLE;

ANTIFUNGAL ACTIVITY; ASPERGILLOSIS; CANDIDIASIS; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONFERENCE PAPER; DRUG COST; HUMAN; IMMUNE DEFICIENCY; INFECTION PREVENTION; INTRANASAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MORTALITY; MYCOSIS; NEPHROTOXICITY; NEUTROPENIA; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL;

EID: 0030902864     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (3)

1. Wade JC. Febrile neutropenia. In: Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE (eds). Clinical Oncology. Churchill Livingstone: New York. 1995:485-500.
2. Wald A, Leisenring W, van Burk JA, et al. Natural history of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. Ann Intern Med 1997 (in press).
3. Goodrich JM, Reed EC, Mori M, et al. Clinical features and analysis of risk factors for invasive candidal infection after marrow transplantation. ; Infect Dis 1991 ; 164:731-740.